Europe Fluorescent in Situ Hybridization (FISH) Market, By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others) - Industry Trends and Forecast to 2030.
Europe Fluorescent in Situ Hybridization (FISH) Market Analysis and Insights
The rising public awareness regarding cancer and genetic disorders has enhanced the demand for the market. The major market players focus on various product launches and approvals during this crucial period. In addition, the increase in improved and advanced procedures of FISH also contributes to the rising demand for the market.
The Europe Fluorescent in Situ Hybridization (FISH) market is expected to grow in the forecast period of 2023 to 2030 due to the rise in cancer and other chronic diseases. The high funding for research activities by the government and other bodies is also expected to drive market growth. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market. However, the high cost of the FISH techniques in the treatment procedure is expected to restrain the market growth. Increasing demand for specific biomarkers and various probes is expected to provide the opportunity for market growth to enhance the treatment. The growing demand for better quality healthcare for genetic disorders and the rising adoption of personalized medicine is expected to boost the market growth. However, the ethical concerns associated with FISH technology and the lack of skilled and certified professionals are expected to challenge market growth.
Data Bridge Market Research analyzes that the Europe Fluorescent in Situ Hybridization (FISH) market is expected to reach a value of USD 474.68 million by 2030, at a CAGR of 7.5% during the forecast period. The product type segment accounts for the largest segment in the market due to the rising number of breast cancer and genetic disorders among patients. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, and Pricing in USD
|
|
Segments Covered
|
By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and rest of Europe
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others
|
Market Definition
A molecular cytogenetic technique called Fluorescence in Situ Hybridization (FISH) enables the localization of a particular DNA sequence or an entire chromosome in a cell. It is used to diagnose genetic disorders, map genes, identify chromosomal anomalies, and may also be used to compare how the genes on different chromosomes in related species are organized. While performing FISH, the double helix structure is unwound and all probes connected to fluorescent molecules are bound to a particular sequence of sample DNA that can be seen under a fluorescence microscope.
FISH is frequently used for diagnostic purposes in oncology, preventative and reproductive health, and genomic and cell biology research. It is the industry-recognized method for finding infectious illnesses and chromosomal abnormalities. However, strict regulations and standards for the approval of FISH products and probes are expected to restrain the market growth.
Europe Fluorescent in Situ Hybridization (FISH) Market Dynamics
This section deals with the understanding of market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Burden of Genetic Disorders as Well as Cancer
Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, are driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques, which drives market growth.
- Innovation and Advancements in FISH Products
The most reliable method for finding specific DNA sequences, diagnosing genetic illnesses, mapping genes, and discovering new oncogenes or genetic abnormalities causing various cancers is FISH. Recent advancements in the technology have made it possible to screen the entire genome concurrently utilizing array-based methods such as comparative genomic hybridization or multiplex FISH with multicolor whole chromosome probes. In the fight against genetic diseases, FISH has fundamentally transformed the field of cytogenetics and is now acknowledged as a trustworthy diagnostic and research tool, which drives market growth.
Restraint
- High Cost of FISH Testing
The macromolecule recognition technique known as FISH relies on the complementary nature of DNA or DNA/RNA double strands. The FISH test "maps" the genetic material present in human cells, including particular genes or gene segments. A FISH test is helpful for diagnosing some types of cancer because it can find genetic abnormalities linked to the disease. Cost issues are of utmost relevance in the modern molecular diagnostic laboratory. In addition to enabling a laboratory to handle increased test volumes and throughput, automation of complicated molecular assays also significantly reduces the cost of testing from the standpoint of reagent expenses, which restrains market growth.
Opportunity
- Rising Public Awareness about the Early Detection of Genetic Abnormalities
Genetic testing aids patients in making important decisions in the prevention, treatment, or early detection of hereditary disorders. Low awareness of the importance of genetic testing contributes to the increase in the incidence of hereditary disorders.
A genetic disorder is a health condition that is inherited by a person, usually caused by mutations in the DNA or changes in the number or overall structure of chromosomes. Several types of commonly known diseases have been determined to be related to hereditary gene mutations.
Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.
Challenge
- Stringent Government Regulations for the Approval of FISH Probes
The use of FISH techniques across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases, which are preventable by early diagnosis and timely treatments. At the same time, the players of the FISH technology in the market have to follow certain regulations to get approval from the upper authorities for launching the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks of all the steps. The pre-market approval of various medical devices varies from one country to another.
Post-COVID-19 Impact on Europe Fluorescent in Situ Hybridization (FISH) Market
The pandemic has had adverse impacts on the FISH manufacturers as well as users. The market has been significantly influenced by COVID-19, which has led to an increase in research studies utilizing FISH. One such study, published in November 2022 in the PLOS One Journal, employed a FISH-based method to detect SARS-CoV-2 in saliva. The method involved using a Cy3-labeled DNA probe specific to SARS-CoV-2, and the analysis was carried out manually using fluorescence microscopy as a proof-of-concept.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the FISH market.
Recent Developments
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a Europe scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the Europe market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
Europe Fluorescent in Situ Hybridization (FISH) Market Scope
The Europe Fluorescent in Situ Hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- CONSUMABLES
- INSTRUMENT
- SOFTWARE
Based on product type, the market is segmented into consumables, instrument, and software.
BY TECHNOLOGY
- DNA FLUORESCENT IN SITU HYBRIDIZATION
- RNA FLUORESCENT IN SITU HYBRIDIZATION
- PNA FLUORESCENT IN SITU HYBRIDIZATION
- OTHERS
Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
BY APPLICATION
- CANCER RESEARCH
- GENETIC RESEARCH
- INFECTIOUS DISEASE
- PERSONALIZED MEDICINE
- OTHER
Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
BY USAGE
- CLINICAL
- RESEARCH
- COMPANION DIAGNOSTIC
Based on usage, the market is segmented into clinical, research, and companion diagnostic.
BY END USER
- HOSPITALS & CLINICS
- DIAGNOSTIC LABORATORIES
- PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANISATIONS
- ACADEMIC & RESEARCH ORGANISATIONS
- OTHERS
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.
BY DISTRIBUTION CHANNEL
- RETAIL SALES
- DIRECT TENDER
- ONLINE SALES
- OTHERS
Based on distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
Europe Fluorescent in Situ Hybridization (FISH) Market Regional Analysis/Insights
The Europe Fluorescent in Situ Hybridization (FISH) market is analyzed and market size information is provided based on product type, technology, application, usage, end user, and distribution channel.
The countries covered in this market report are Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and the rest of Europe.
Germany is expected to dominate the Europe region due to the mass production of FISH treatment consumables & kits and increasing demand from emerging markets, and expansion of venous disease treatment industries.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Fluorescent in Situ Hybridization (FISH) Market Share Analysis
The Europe Fluorescent in Situ Hybridization (FISH) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the Europe Fluorescent in Situ Hybridization (FISH) market are Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others.
SKU-